General Information of Drug (ID: DMHPD2Y)

Drug Name
SODIUM CITRATE
Synonyms
Sodium citrate; 68-04-2; TRISODIUM CITRATE; Citrosodine; Sodium citrate anhydrous; Citrosodina; Natrocitral; Citrosodna; Citreme; Citnatin; sodium citrate, anhydrous; Sodium 2-hydroxypropane-1,2,3-tricarboxylate; Trisodium citrate anhydrous; Citric acid, trisodium salt; Trisodium citrate, anhydrous; Citric acid trisodium salt; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt; UNII-RS7A450LGA; FEMA No. 3026; CCRIS 3293; Sodium citrate (Na3C6H5O7); HSDB 5201; EINECS 200-675-3; RS7A450LGA; CHEBI:53258; Trisodium 2-hydroxy-1
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 258.07
Topological Polar Surface Area Not Available
Rotatable Bond Count 2
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.6-2.1 h [2]
Clearance
The total body clearance of drug is 313-1107 mL/min [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 - 54 minutes [2]
Metabolism
The drug is metabolized via the liver [3]
Vd
The volume of distribution (Vd) of drug is 19-39 L [2]
Chemical Identifiers
Formula
C6H5Na3O7
IUPAC Name
trisodium;2-hydroxypropane-1,2,3-tricarboxylate
Canonical SMILES
C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+].[Na+].[Na+]
InChI
InChI=1S/C6H8O7.3Na/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
InChIKey
HRXKRNGNAMMEHJ-UHFFFAOYSA-K
Cross-matching ID
PubChem CID
6224
ChEBI ID
CHEBI:53258
CAS Number
68-04-2
DrugBank ID
DB09154
TTD ID
D05KTE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carbonic anhydrase IV (CA-IV) TTZHA0O CAH4_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carbonic anhydrase IV (CA-IV) DTT CA4 1.58E-77 -2.02 -1.77
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from SODIUM CITRATE (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Pexidartinib DMS2J0Z Moderate Decreased absorption of SODIUM CITRATE due to altered gastric pH caused by Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [11]
HKI-272 DM6QOVN Moderate Decreased absorption of SODIUM CITRATE due to altered gastric pH caused by HKI-272. Breast cancer [2C60-2C6Y] [12]
GSK1265744 DMT8J0I Moderate Decreased absorption of SODIUM CITRATE due to altered gastric pH caused by GSK1265744. Human immunodeficiency virus disease [1C60-1C62] [13]
Acalabrutinib DM7GCVW Moderate Decreased absorption of SODIUM CITRATE due to altered gastric pH caused by Acalabrutinib. Mature B-cell lymphoma [2A85] [14]
Choline salicylate DM8P137 Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. SODIUM CITRATE caused by Choline salicylate mediated altered urine pH. Postoperative inflammation [1A00-CA43] [15]

References

1 Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
2 Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003 Oct;31(10):2450-5.
3 Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22.
4 Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
5 Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
8 Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
9 Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
10 Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
11 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
12 Product Information. Nerlynx (neratinib). Puma Biotechnology, Inc., Los Angeles, CA.
13 Cerner Multum, Inc. "Canadian Product Information.".
14 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
15 Balali-Mood M, Prescott LF "Failure of alkaline diuresis to enhance diflunisal elimination." Br J Clin Pharmacol 10 (1980): 163-5. [PMID: 7426277]